glucose drug
Evidence from:
primary |
all sources
Related entities (9)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| Cyp2a5 | regulates | glucose | — | 1 |
| CYP2A6 | regulates | glucose | — | 1 |
| glucose | associated_with | Glucose tolerance test | — | 1 |
| glucose | risk_factor_for | obesity | — | 1 |
| high-fat diet | risk_factor_for | glucose | — | 1 |
| NaOH | interacts_with | glucose | — | 1 |
| NaOH | regulates | glucose | — | 1 |
| PPARA | associated_with | glucose | — | 1 |
| PPARα | regulates | glucose | — | 1 |
Mentioned in (29)
Papers in which this entity is mentioned.
- Large language model agents for biological intelligence across genomics, proteomics, spatial biology, and biomedicine. (2026)
- Single-cell exon deletion profiling reveals splicing events that shape gene expression and cell state dynamics. (2026)
- Specificity, length and luck drive gene rankings in association studies. (2026)
- Concordance between male- and female-specific GWAS results helps define underlying genetic architecture of complex traits. (2025)
- Biomni: A General-Purpose Biomedical AI Agent. (2025)
- Tracing the evolution of single-cell 3D genomes in Kras-driven cancers. (2025)
- Parent-of-origin effects on complex traits in up to 236,781 individuals. (2025)
- Alcohol Exposure May Increase Prenatal Choline Needs Through Redirection of Choline into Lipid Synthesis Rather than Methyl Donation. (2025)
- Reduction of APOE accounts for neurobehavioral deficits in fetal alcohol spectrum disorders. (2024)
- Alcohol and Immunology: Mechanisms of multi-organ damage. Summary of the 2022 alcohol and Immunology research interest group (AIRIG) meeting. (2023)
- Alternative splicing events as peripheral biomarkers for motor learning deficit caused by adverse prenatal environments. (2023)
- Single-cell genomic variation induced by mutational processes in cancer. (2022)
- Detecting cell-type-specific allelic expression imbalance by integrative analysis of bulk and single-cell RNA sequencing data. (2021)
- UMI-linked consensus sequencing enables phylogenetic analysis of directed evolution. (2020)
- Alterations in the whole brain network organization after prenatal ethanol exposure. (2020)
- Emerging Roles of SRSF3 as a Therapeutic Target for Cancer. (2020)
- Kcnn2 blockade reverses learning deficits in a mouse model of fetal alcohol spectrum disorders. (2020)
- Neoadjuvant checkpoint blockade for cancer immunotherapy. (2020)
- Detecting cell-type-specific allelic expression imbalance by integrative analysis of bulk and single-cell RNA sequencing data (2020)
- Differential sensitivity of human neurons carrying μ opioid receptor (MOR) N40D variants in response to ethanol. (2020)
- Functional Connectivity and Metabolic Alterations in Medial Prefrontal Cortex in a Rat Model of Fetal Alcohol Spectrum Disorder: A Resting-State Functional Magnetic Resonance Imaging and in vivo Proton Magnetic Resonance Spectroscopy Study. (2019)
- CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model. (2019)
- Maternal circulating miRNAs that predict infant FASD outcomes influence placental maturation. (2019)
- GeneGini: Assessment via the Gini Coefficient of Reference "Housekeeping" Genes and Diverse Human Transporter Expression Profiles. (2018)
- The Ontology for Biomedical Investigations. (2016)
- What Happens When Children with Fetal Alcohol Spectrum Disorders Become Adults? (2015)
- Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. (2012)
- Effects of ethanol and NAP on cerebellar expression of the neural cell adhesion molecule L1. (2011)
- Chronic binge ethanol-mediated acidemia reduces availability of glutamine and related amino acids in maternal plasma of pregnant sheep. (2008)
Merged raw entities (27)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| glucose | drug | 149 | 288 |
| d-glucose | drug | 14 | 16 |
| blood glucose | phenotype | 13 | 21 |
| glucose | phenotype | 10 | 18 |
| blood glucose level | phenotype | 9 | 19 |
| plasma glucose | phenotype | 8 | 11 |
| glucose level | phenotype | 7 | 10 |
| blood glucose levels | phenotype | 5 | 10 |
| blood glucose | drug | 4 | 5 |
| plasma glucose | drug | 3 | 3 |
| serum glucose | phenotype | 2 | 2 |
| blood glucose level | drug | 1 | 1 |
| blood glucose levels | drug | 1 | 1 |
| 20% (w : v) glucose | drug | — | — |
| 75 g oral glucose | drug | — | — |
| baseline blood glucose level | drug | — | — |
| baseline glucose | drug | — | — |
| baseline glucose levels | drug | — | — |
| blood glucose recovery | drug | — | — |
| early morning non-fasted glucose level | drug | — | — |
| glucose homeostasis | drug | — | — |
| glucose level | drug | — | — |
| glucose levels | drug | — | — |
| glucose values | drug | — | — |
| pre-treatment blood glucose level | drug | — | — |
| pre-treatment glucose level | drug | — | — |
| serum glucose | drug | — | — |